RISK STRATIFICATION IN HEART FAILURE USING
123I-mIBG. 
Introduction
Heart failure (HF) is a progressive, heterogeneous form of cardiovascular disease that requires treatment to be individualised depending on the presenting symptoms. HF is the inability of the left ventricle (LV) to fill or eject enough blood to meet the requirements of the body (1) and might be viewed as a syndrome representative of a variety of cardiac diseases (2) . Nonetheless, coronary artery disease (CAD) is the underlying pathology in 70% of HF patients (3) . Chronic heart failure (CHF) involves both mechanical failure and autonomic nervous system dysfunction which can lead to sudden cardiac death (SCD). A number of therapies are, therefore, utilised including pharmaceutical and device options; for example the implantable cardioverter/defibrillator (ICD) device. Despite these options, the long term prognosis in HF is poor with 5 year mortality rates of 59% and 45% for men and women respectively (3) . There is a clear need for improved stratification of patients based on risk yet there is a paucity of screening programs available for early detection (2) .
A decision to use an ICD is based on CHF patients presenting with a New York Heart Association (NYHA) classification of II or III and a left ventricular ejection fraction (LVEF) less than or equal to 30-35%; depending on the country. A large percentage of ICD devices, however, never deliver therapy during their lifetime while as many as 33% of patients ineligible for an ICD (LVEF > 35%) die of SCD (4) . Consequently, there is a pressing need for improved differentiation of CHF, regardless of the LVEF, to better identify those in whom an ICD is more likely to reap benefits. In the USA, scintigraphy with 123-iodine meta-iodobenzylguanidine ( 123 I-mIBG) has been used for risk stratification in CHF patients with low LVEF (< 35%). 123 I-mIBG identifies sympathetic nervous system dysfunction and has been shown to lead to better patient stratification (4) .
Heart Failure HF has been described as the Age is a very good predictor of the incidence of HF. HF incidence is 10 per 1000 of the population for those over 65 years of age and 20% of hospitalsiations are in those of 65 years of age (2) . For those 50-59 years of age, the prevalence is 8 per 1000 for both men and women, however, this sharply increases for those 80-89 years to 66 per 1000 and 79
per 1000 for men and women respectively (1).
HF has a median survival of just 1.7 years and 3.2 years for men and women respectively (1) . It has a 10% mortality by 30 days, which highlights an early high risk period of disease. This high risk period is followed by a 5 year mortality rate of 54% and 40% for men and women respectively (9) . CHF is progressive in nature and ultimately fatal which makes early detection crucial for delaying progression. For patients with mild symptoms, the annual death rate is 5-10% and this increases sharply to 30-40% for those with more advanced symptoms (10).
Although HF is generally classified according to the NYHA classification ( Medicare Australia provide coverage for CHF patients with NYHA class II or III symptoms, an LVEF of less than or equal to 35% and after receiving optimised medical therapy. Patients treated with an ICD have a 1-3% annual decrease in absolute mortality which equates to a 20-30% relative reduction in mortality each year. The VALIANT trial reported on 14609 patients with LVSD or HF after myocardial infarction (MI) and found a mortality rate of 6.2% after a median 24.7 month follow up (13) . Analysis revealed that each decrease of 5 points of LVEF was associated with a 21% adjusted increase in risk of mortality (13) . The MADIT-CRT trial recruited 1232 patients with previous MI and a LVEF less than 30% and reported that, compared to standard medical therapy, the addition of an ICD improved the 20 month follow up mortality rate from 19.8% to 14.2% (14) .
Cardiac Autonomic Neuropathy in Heart Failure
The compensatory response of the autonomic nervous system to LV dysfunction in HF becomes part of the disease progress leading eventually to further deterioration of the disease. The sympathetic nervous system is part of this response. The ventricular innervation is characterised by a gradient from base to apex (15) . Chronic impairment in cardiac output due to damage to the cardiac pump increases plasma noradrenaline levels released from sympathetic postganglionic nerves. This sympathetic overdrive, which is related to dysfunctional atrial baroreceptor reflex activity and sympatho-vagal balance, parallels the clinical severity of HF expressed by the NYHA functional class categories and is similar in ischaemic or non-ischaemic heart failure states (16) .
I-mIBG in Heart Failure
Molecular imaging of the cardiac sympathetic neuronal system is possible with 123 I-mIBG because it is a false adrenergic neurotransmitter that has a similar re-uptake mechanism as norepinephrine. Fortunately, 123 I-mIBG is not metabolised and does not interact with post-synaptic receptors which allows scintigraphic imaging at early (15 minutes post administration) and delayed (4 hours post administration) phases (17) . Impaired sympathetic innervation has been shown to increase ventricular arrhythmias because even in viable myocardium the impaired innervations results in abnormal chemical and electrical stimulation (18) . Since the sympathetic nervous tissue is more sensitive to ischaemia than the myocardium, impaired innervations can cause arrhythmia but be insufficient to cause myocardial infarction (18) . Clinical use is well established for 123 ImIBG and its safety profile is well documented to provide a useful non invasive tool to risk stratify patients with CHF. Greater deprivation of cardiac sympathetic innervation is associated with a worse prognosis in heart failure patients (19) .
Generally speaking, the delayed uptake (H:M) has been shown to have predictive power although washout rate and defect score have also been reported to be clinical important.
Nonetheless, the correlation between LVEF and H:M is weak (r = 0.50) (20) . While CHF can show an initial compensatory increase in myocardial uptake of 123 I-mIBG, low uptake is strongly correlated with a poor prognosis and predicts increased risk of arrhythmia and SCD (21) . More recently, the washout rate of 123 I-mIBG from the myocardium between early and delayed images has shown promising predictive power (3) . HF is associated with more rapid washout while even in the presence of HF, the washout rates of lung, liver and mediastinum appear uniform (21) . Washout greater than 27% has been reported as a strong predictor of survival but not necessarily of cardiac events (22) . One might consider the late uptake a marker for risk of SCD and washout a marker of survival independent of SCD risk (ie. death due to disease progression). Together, they might provide better stratification of those suitable for ICD with uptake identifying those likely to benefit and washout those less likely to benefit. Table 2 Failure study) (23). The study included 961 patients with a NYHA II or III classification and a LVEF of 35% or less that followed them for two years. The results indicated that normal (using a delayed heart to mediastinum ratio [H:M] of 1.60 as the cut-off) 123 ImIBG uptake was associated with an 85% event free two year period while abnormal 123 ImIBG only had a 63% 2 year event free period. The investigation also showed that H:M less than 1.20 had a 10 fold increase in event rate over those greater than or equal to 1.60.
Carrio et al (9) used a delayed H:M of 1.75 as the cut-off and improved sensitivity to 84% (specificity 60%) to predict events with a 95% event free survival for 2 years greater than or equal to 1.75 and 62% for those lower than 1.75 (9).
In a 2-year follow-up period in CHF patients, using 123 I-mIBG SPECT to show that appropriate ICD discharge was documented in 21% of patients and patients with greater defect scores showed a 10-fold higher likelihood of appropriate ICD discharge therapy advanced heart failure to show that a high defect score (<26) determined by regional summation on SPECT was predictive of appropriate ICD discharge. The late mIBG defect score was also independently predictive of appropriate ICD discharge. Indeed, patients with a late mIBG SPECT summed defect score greater than 26 were associated with a 52% appropriate discharge rate compared to just 5% for those with lower defect scores (p < 0.01).
Clinical Case
A 77 year old male presented with dyspnoea on exertion and ischaemic cardiomyopathy secondary to a history of myocardial infarction in the inferior wall and coronary artery with medium energy general purpose collimation was employed. Planar imaging was followed by 180 degree SPECT (LPO45 to RAO45) using a 64 matrix, 60 projections at 25 seconds per projection. The patient was imaged supine with the arms extended above the head. The SPECT study was reconstructed using CT based attenuation correction.
The planar and SPECT acquisitions were repeated 4 hours post IV. Global myocardial, mediastinal, lung and liver regions of interest were applied to the planar images.
Normalised (counts per pixel) H:M were calculated for both the early phase (2.15) and delayed phase (2.21) using previously described methods (25) (26) (27) . Delayed image statistics were decayed corrected. The global washout rate from early to delayed phases was calculated for myocardium, mediastinum, lung and liver. Cardiac washout rate was determined as 35.0% by (25) (26) (27) :
[ early phase counts per pixel -delayed phase counts per pixel ] x 100 early phase counts per pixel
Regions were applied to the planar image as described by Verberne et al. (28) Thus, more rapid washout might be a marker for making a decision against an ICD.
Normalised (counts per pixel) regions of interest were drawn on mid short axis (SA) and vertical long axis (VLA) SPECT slices (26) . On the SA slice, regions included anterior, septal, lateral and inferior walls. One the VLA slice, the region included apex. Matsuo et al. (29) used 5x5 pixel regions in the basal and distal SA slice for anterior, lateral, septal and inferior walls plus apex on the VLA. Our approach was to use the mid SA slice and mid VLA slice to generate regions for each wall using larger regions that represented the entire territory (ie. anterior, lateral, spetal, inferior and apex). The 4 hour data were decay corrected and regional washout rates (RW) and uptake index (MUP) were determined (table 4) using the method described by Zhao et al. (26) Tc-MIBI perfusion. Indeed, both wall motion and wall thickening are noted in these regions on the perfusion study. The global 123 I-mIBG findings reflect sympatheic change associated with infarct not just progression of HF. Interestingly, the non MI region of greatest 123 I-mIBG washout (apex) was also the region with the greatest thickening (apex).
Despite satisfying the criteria to receive an ICD under the Medicare scheme, an ICD was not implanted and the patient remains event free at 12 months follow-up.
Discussion
The cost effectiveness of ICD therapy remains controversial. While ICDs have proven value in reducing mortality in CHF, they remain expensive so identifying those patients who would benefit most from an ICD is crucial. SCD occurs more commonly in those with LVEF over 35% with 67% of SCD having a LVEF over 35% and only 33% of SCD patients having a LVEF less than or equal to 35% (4). This no doubt reflects the high number of patients with an LVEF under 35% who die of progressive HF rather than SCD.
In addition, a substantial number of patients with an ICD and LVEF < 35% never see it deliver therapy during its lifetime. The ability to accurately stratify those patients with a low LVEF in whom an ICD is not indicated (discharge unlikely or CHF progression fatal) and those with a higher LVEF in whom it is (SCD likely) would minimise unnecessary health expenditure and decrease preventable deaths respectively. There is a paucity of literature examining the predictive capability of 123 I-mIBG in the above 35%
LVEF group.
Reliance on LVEF is a poor predictor of who does and does not need ICD. An LVEF greater than or equal to 30% with a delayed 123 I-mIBG heart to mediastinum ratio greater than or equal to 1.60 is associated with zero deaths in the two year follow-up period (23) .
The same LVEF stratification, however, with a heart to mediastinum ratio less than 1.60 has a greater cumulative two year mortality than those with an LVEF less than 30% and a heart to mediastinum ratio greater than 1.60. Naturally, LVEF and a heart to mediastinum ratio lower than 30% and 1.60 respectively are associated with the greatest two year mortality. There is no specific line above or below which a decision can be made to use ICD or not. While the literature to date indicates 123 I-mIBG to be a reliable and strong predictor of events, it does not provide sufficient discriminatory power to direct a decision to either offer ICD in those with a LVEF over 35% or to decline the ICD option in those with an LVEF below 35%. The discriminatory power is perhaps reduced due to the global approach to calculations. That is, cardiac autonomic neuropathy (CAN) progression begins in the inferior wall of the heart and progresses through adjacent myocardial walls (lateral and septal) before eventually reaching the anterior wall (30) .
Normal global uptake may reflect anterior wall uptake and fail to highlight early CAN in the inferior wall.
There is a need for further evaluation of the role of both planar and SPECT 123 I-mIBG in stratification of heart failure patients. In particular, to more accurately identify patients with a LVEF less than 35% who are unlikely to benefit from the ICD and to identify those with an LVEF over 35% in whom ICD is likely to be life saving. This approach will result in a more cost effective heart failure management; both decreasing health care costs and increasing lives saved. This case highlights a patient eligible for ICD based on standard criteria but in whom the global and regional 123 I-mIBG study suggest that ICD implantation is not ideal.
Conclusion
While 123 I-mIBG imaging and global analysis provides a useful tool to direct appropriate HF treatment options in a patient eligible of ICD implantation, the discriminatrory power of regional quantitation using SPECT data adds an important dimension that warrants further clinical investigation. While delayed H:M ratios provide improved stratification of HF patients over LVEF and HF classification, the washout rate provides an important marker for identifying more rapid disease progression and lower likelihood of a benefit from ICD. Further research is required for both global and regional quantitation in this patient group. Table 1 : NYHA and ACC/AHA classifications for heart failure. The arrows indicate the potential directions of stage progression for each. Horizontal alignment provides an indicator of corresponding stages between the two classifications. Table 3 : H:M and washout rates for optimistic and pessimistic approaches to region of interest placement. The tabulated data shows some variability, however, best and worst cases are consistent with a low risk H:M ratio and abnormal washout. Table 4 : Regional anslysis on SPECT. (26) using SPECT. Figure 1 : Anterior lanar images demonstrating the global accumulation of 123 I-mIBG in the myocardium at 15 minutes (A) and 4 hours (B) after injection. The red regions represent the standard global regions of interest while the blue regions are those modified and described above. Lung and liver regions are in purple. The images highlight the need for greater discriminatory power using SPECT. Nonetheless, it is apparent that the heart to mediastinum ratio is in the order of 2 and that there is marked washout at 4 hours. . The arrows highlight areas of decreased perfusion and denervation in the distal LAD region that show both thickening and motion. The septal paradoxical motion can be appreciated and the inferior and infero-lateral hypokinesia is also apparent.
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